Abstract

Hyperactivated ribosome biosynthesis is attributed to a need for elevated protein synthesis that accommodates cell growth and division, and is characterized by nucleomorphometric alterations and increased nucleolar counts. Ribosome biogenesis is challenged when DNA-damaging treatments such as radiotherapy are utilized. Tumor cells that survive radiotherapy form the basis of recurrence, tumor progression, and metastasis. In order to survive and become metabolically revitalized, tumor cells need to reactivate RNA Polymerase I (RNA Pol I) to synthesize ribosomal RNA, an integral component of ribosomes. In this study, we showed that following radiation therapy, tumor cells from breast cancer patients demonstrate activation of a ribosome biosynthesis signature concurrent with enrichment of a signature of Hedgehog (Hh) activity. We hypothesized that GLI1 activates RNA Pol I in response to irradiation and licenses the emergence of a radioresistant tumor population. Our work establishes a novel role for GLI1 in orchestrating RNA Pol I activity in irradiated breast cancer cells. Furthermore, we present evidence that in these irradiated tumor cells, Treacle ribosome biogenesis factor 1 (TCOF1), a nucleolar protein that is important in ribosome biogenesis, facilitates nucleolar translocation of GLI1. Inhibiting Hh activity and RNA Pol I activity disabled the outgrowth of breast cancer cells in the lungs. As such, ribosome biosynthesis and Hh activity present as actionable signaling mechanisms to enhance the effectiveness of radiotherapy.

Details

Title
Ribosome biosynthesis and Hedgehog activity are cooperative actionable signaling mechanisms in breast cancer following radiotherapy
Author
Metge, Brandon J. 1   VIAFID ORCID Logo  ; Alsheikh, Heba A. 1   VIAFID ORCID Logo  ; Chen, Dongquan 2 ; Elhamamsy, Amr R. 1 ; Hinshaw, Dominique C. 1 ; Chen, Bo-Ruei 3 ; Sleckman, Barry P. 3 ; Samant, Rajeev S. 4 ; Shevde, Lalita A. 5   VIAFID ORCID Logo 

 University of Alabama at Birmingham, Department of Pathology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187) 
 University of Alabama at Birmingham, Division of Preventive Medicine, Department of Medicine, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, Center for Clinical and Translational Sciences, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187) 
 University of Alabama at Birmingham, O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, Division of Hematology Oncology, Department of Medicine, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187) 
 University of Alabama at Birmingham, Department of Pathology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); Birmingham VA Medical Center, Birmingham, USA (GRID:grid.280808.a) (ISNI:0000 0004 0419 1326) 
 University of Alabama at Birmingham, Department of Pathology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187) 
Pages
61
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
ISSN
2397768X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2830505391
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.